Defendant

Opiant Pharmaceuticals, Inc.

4 cases as defendant.

Cases: 4
Active: 1; 3 closed
Filed: 2019
Top venue: PTAB; 3 cases

Also appears as a plaintiff in 3 cases → View as plaintiff

Nalox-1 Pharmaceuticals LLC v. Opiant Pharmaceuticals, Inc.

IPR petitions filed

Docket:: IPR2019-00685; IPR2019-00688; IPR2019-00691; IPR2019-00694
Court:: Patent Trial and Appeal Board
Filed:: 2019-02-19

Patents:9192570 9468747 9561177 9629965 9775838

π Nalox-1 Pharmaceuticals LLC Δ Opiant Pharmaceuticals, Inc.

Nalox-1 filed multiple IPR petitions against Opiant challenging U.S. 9,468,747; 9,561,177; 9,629,965; 9,775,838. The '570 patent was not challenged; it was cited as prior art (Wyse).

Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Ltd. et al.

institution denied

Docket:: IPR2019-00697
Court:: Patent Trial and Appeal Board
Filed:: 2019-02-19
Terminated:: 2019-10-16

Patents:9775838

π Nalox-1 Pharmaceuticals, LLC Δ Adapt Pharma Ltd.Δ Opiant Pharmaceuticals, Inc.

Inter partes review petition against U.S. 9,775,838. Institution denied on Oct. 16, 2019.

Nalox-1 Pharmaceuticals, LLC v. Adapt Pharma Limited et al.

institution denied

Docket:: IPR2019-00698
Court:: Patent Trial and Appeal Board
Filed:: 2019-02-19
Terminated:: 2019-10-16

Patents:9775838

π Nalox-1 Pharmaceuticals, LLC Δ Adapt Pharma Limited Δ Opiant Pharmaceuticals, Inc.

Inter partes review petition against U.S. 9,775,838. Institution denied on Oct. 16, 2019 (Paper 13); Board found prior art teaches away.

Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.

Final Written Decision

Docket:: IPR2019-00685
Court:: USPTO Patent Trial and Appeal Board
Filed:: 2019-02-19
Terminated:: 2020-08-21

Patents:9211253

π Nalox-1 Pharmaceuticals, LLC Δ Opiant Pharmaceuticals, Inc.

Inter partes review challenging all claims 1-29 of US 9,211,253. Instituted August 27, 2019; Final Written Decision entered August 21, 2020. The narrative does not state the substantive outcome of the Final Written Decision.